Chief executives Henri Termeer (left) of Genzyme and James C. Mullen of Biogen Idec at the MassBio meeting yesterday.
(Pat Greenhouse/Globe Staff)
Biotech executives opine on health care law
Mullen says little done to curb costs; Termeer applauds innovation
Chief executives Henri Termeer (left) of Genzyme and James C. Mullen of Biogen Idec at the MassBio meeting yesterday.
(Pat Greenhouse/Globe Staff)
Top executives of the state’s two largest biotechnology companies offered diverging views yesterday on the health care bill signed into law by President Obama, with one contending it protects innovation and the other insisting it does little to control costs. (Full article: 643 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
Waiting for Twitter to feed in the latest...